|
?:abstract
|
-
The COVID-19 pandemic impacts the hematology practice Intensive chemotherapies for high-grade lymphomas and acute leukemias, multiple myeloma treatments and most hematopoietic stem cell transplantations should be performed as usual Low-grade lymphomas should only be treated when strictly indicated, maintenance can be postponed Other myeloid neoplasia and their therapies cause imunosupression;dose adjustment is recommended but no brisk stopping Sickle cell anemia patients are highly succeptible to severe COVID-19 course Thrombocytopenia and procoagulant state are associated with severe courses of COVID-19, requiring an individualized therapy No data indicate a risk of SARS-CoV-2 transmission through blood product transfusion La pandemie de COVID-19 affecte la prise en charge hematologique Les chimiotherapies intensives pour les lymphomes agressifs et les leucemies aigues, les traitements du myelome multiple, ainsi que la plupart des greffes de cellules souches hematopoietiques doivent continuer a etre pratiquees Les lymphomes de bas grade seront traites uniquement avec des indications claires ;et la maintenance repoussee Les autres neoplasies myeloides et leurs traitements causent une immunosuppression ;on recommande une adaptation des doses, mais pas darret brusque La drepanocytose rend les patients tres vulnerables au COVID-19 La thrombopenie signe un etat procoagulant et la severite du COVID-19, necessitant un traitement individualise Aucune donnee nindique de risque dune transmission du SARS-CoV-2 par transfusion de produits sanguins
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}